Trending/ESMO 2014 Congress
- September 29, 2014
Data From Worldwide Trial of Two HER2-Positive Breast Cancer Drugs Shows That Trastuzumab Should Remain as Standard of Care
JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast…
No information found.